But somehow, the excitement was over, and subsequent research became more “routine.” The characterization of the CCR5 Δ32 mutation and its consequences on infection rate by HIV had validated CCR5 as an obvious target for the development of drugs targeting CCR5 and the entry of macrophage-tropic HIV strains. This evidence concerns the gene CCR5 and infection.